Pharmaceutical News

RSS

Study results from US Military Malaria Vaccine Program announced

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that the US Military Malaria Vaccine Program presented results of its study using the Biojector2000 with a recombinant DNA vaccine at two recent conferences. A Cooperative Research and Development Agreement was signed with the Navy in April 2009 to work together on the study.

28 Apr 2010

Shire receives Paragraph IV Notice Letter from Anchen over filing of ANDA for generic INTUNIV

Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine hydrochloride extended release tablets, INTUNIV(TM).

28 Apr 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

Usually when all else fails with a technical device, a "reset" button can be pressed, preventing a glitch from going any further. What if that could be done with threats to a person's health? Investigators from The Cancer Institute of New Jersey and the Environmental & Occupational Health Sciences Institute which is jointly administered by UMDNJ-Robert Wood Johnson Medical School and Rutgers, The State University of New Jersey, have discovered that a form of a dietary trace element known as selenium can help reset a cell's "biological clock" when it is disrupted by a chemical cancer-causing agent (carcinogen).

28 Apr 2010

AstraZeneca to pay $520 million in largest pharmaceutical civil settlement

AstraZeneca will pay the federal government $520 million in civil fines to settle charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement and among the top five civil and criminal drug company settlements in U.S. history.

28 Apr 2010

International initiative seeks to reduce heterosexual HIV transmission

Los Angeles Biomedical Research Institute has received a $350,000 grant to study the safety of a gel designed to reduce the heterosexual transmission of HIV from the International Partnership for Microbicides, a nonprofit global initiative to develop products to reduce HIV transmission, and the U.S. Agency for International Development, the Institute announced today.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Hana Biosciences announces completion of Marqibo pre-NDA meeting with FDA

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the Company has completed a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) related to its lead product candidate, Marqibo for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL).

28 Apr 2010

Tamiflu and two other drugs used to treat influenza appear safe for pregnant women and babies: Study

Tamiflu and two other drugs used to treat influenza appear safe for pregnant women and their babies, researchers at UT Southwestern Medical Center have found in a retrospective study of 239 cases of women who received the medications during pregnancy.

28 Apr 2010

Freedland Russo announces $520M settlement over Seroquel marketing practice lawsuit against AstraZeneca

Freedland Russo is pleased that Eric Holder, U.S. Attorney General, announced the $520 million dollar settlement of a lawsuit filed against AstraZeneca. The settlement announced today in Philadelphia indicates marketing practices for Seroquel included promotion of the drug by physicians participating in clinical studies and drug sales representatives encouraging doctors to prescribe for the unapproved uses.

28 Apr 2010

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.

28 Apr 2010

TYRX receives FDA marketing clearance for AIGISRx ST antibacterial patch for soft tissue repair

TYRX, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market AIGISRx® ST, its antibacterial product for the surgical repair of damaged or ruptured soft tissue.

28 Apr 2010

DRCR Network study finds new treatment more effective

A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration.

28 Apr 2010

A bitter pill to swallow

Reporting for Kaiser Health News in collaboration with The Washington Post, Sandra Boodman writes: "When Jere Carpentier learned last year that she had advanced colon cancer -- her third malignancy in a dozen years -- she worried about spending hours in a clinic tethered to an intravenous line, enduring punishing chemotherapy that would make her hair fall out.

28 Apr 2010

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Priligy - new drug for premature ejaculation

For men suffering from premature ejaculation there may be a new savior in town. The new drug called Priligy is reported to triple the time a man can last in bed. It is currently not licensed in the UK, but is available and licensed for use in a number of other European countries.

28 Apr 2010

Actavis launches Tamsulosin capsules in the U.S.

Actavis Inc., today began shipping Tamsulosin capsules to its customers in the United States. The generic equivalent to Flomax®, Tamsulosin is used to treat benign prostatic hyperplasia (BPH). Actavis is partnering with Synthon Pharmaceuticals to launch and market Tamsulosin capsules in the United States.

28 Apr 2010

Expensive generic drugs cost Australia billions

Consumers and the Australian Government are paying up to 10 times more for generic cholesterol-lowering drugs compared to the United Kingdom, according to research carried out by health economists at the University of Sydney.

27 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, announced today it has received new advertising approval from Shaanxi State Food and Drug Administration for marketing Xin Aoxing Oleanolic Acid Capsules.

27 Apr 2010

Pharmaceutical News

Study results from US Military Malaria Vaccine Program announced

Shire receives Paragraph IV Notice Letter from Anchen over filing of ANDA for generic INTUNIV

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Dietary MSC can help reset cell's biological clock to prevent development of breast cancer: Study

AstraZeneca to pay $520 million in largest pharmaceutical civil settlement

International initiative seeks to reduce heterosexual HIV transmission

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Hana Biosciences announces completion of Marqibo pre-NDA meeting with FDA

Tamiflu and two other drugs used to treat influenza appear safe for pregnant women and babies: Study

Freedland Russo announces $520M settlement over Seroquel marketing practice lawsuit against AstraZeneca

Ranibizumab eye injections plus laser therapy result in dramatic visual improvement

TYRX receives FDA marketing clearance for AIGISRx ST antibacterial patch for soft tissue repair

DRCR Network study finds new treatment more effective

A bitter pill to swallow

AMAG Pharmaceuticals reports Feraheme net product revenues of $13.1M for first-quarter 2010

Priligy - new drug for premature ejaculation

Actavis launches Tamsulosin capsules in the U.S.

Expensive generic drugs cost Australia billions

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News